Last reviewed · How we verify
Time-driven dosing
At a glance
| Generic name | Time-driven dosing |
|---|---|
| Also known as | A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate. |
| Sponsor | HIV Prevention Trials Network |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study (PHASE2)
- Implementation Strategies for Monitoring Adherence in Real Time (NA)
- Impact of Mindfulness on Athletic Performance and Functional Movement in Collegiate Athletes (NA)
- A Brain-Computer Interface-Based Attention Training Program Compared With Methylphenidate and Citicoline
- Sulfamethoxazole Prophylaxis Duration After Renal Transplantation (NA)
- Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients (PHASE1, PHASE2)
- The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP) (PHASE2)
- EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Time-driven dosing CI brief — competitive landscape report
- Time-driven dosing updates RSS · CI watch RSS
- HIV Prevention Trials Network portfolio CI